Gregory Schultz, Ph.D.
Molecular Regulation of Tissue Repair
Dr. Schultz's research focuses on the role of growth factors, cytokines and proteases in regulating normal wound healing in the eye and skin, and how alterations in these key molecular regulators leads to impaired healing (chronic wounds) or excessive healing (fibrosis). For example, a major complication after excimer laser surgery of the cornea is the formation of sub-epithelial scar (fibrosis) that produces vision-disrupting haze. We have established that the transforming growth factor beta (TGF-β) system is the dominant factor responsible for initiating scar formation in the eye and other tissues. We also have shown that the connective tissue growth factor (CTGF) system mediates many of the scarring effects of TGF-β. To develop gene-specific approaches that reduce the actions of TGF-β and CTGF, we utilize multiple approaches, including antisense oligonucleotides, siRNAs and adenoassociated virus (AAV) vectors expressing hammerhead ribozymes that selectively destroy the mRNAs for TGF-β and CTGF. At the other extreme of the wound healing spectrum are chronic (impaired) wounds, which our data indicate are caused by ischemia and the formation of bacterial biofilms that produce chronic inflammation and elevated proteases that degrade factors that are essential for healing. Dr. SchultzŐs lab is developing rapid, point-of-care indicators for assessing levels of proteases, nitric oxide (NOx) and biofilms in wound assessment and is involved in clinical trials testing new drugs that reduce inflammation, inhibit proteases, and promote healing of chronic wounds.
Not Accepting New Students This Year
office: Medical Sciences, M337F
lab: Medical Sciences, M337 E
Professor Gregory S. Schultz earned a Ph.D. degree in Biochemistry from Oklahoma State University in the area of hormonal regulation of breast cancer then completed three years of post-doctoral research in Cell Biology in the laboratory of Dr. James Jamieson at Yale University where he studied angiotensin binding to vascular smooth muscle cells. In 1979 he was appointed Assistant Professor of Biochemistry at the University of Louisville where he began studying growth factor regulation of normal and cancer cells. In 1989, he was appointed Professor of Obstetrics and Gynecology at the University of Florida where he established the multidisciplinary Institute for Wound Research. Dr. Schultz has published more than 220 research papers, chapters and review articles that have been cited more than 6,400 times, and he has over a dozen patents in the area of wound healing. He has received over $11 million in grant funding from the National Institutes of Health, pharmaceutical companies, and the US Army, and he serves as an ad hoc member of NIH study sections. He served as President of the Wound Healing Society from 1999-2001, is the Chair of the Wound Bed Preparation Advisory Board, and serves on the National Pressure Ulcer Advisory Panel. He is on the editorial board of six journals in the areas of ocular and skin wound healing. He is a consultant for multiple biotechnology companies and a founder of QuickMed Technologies and Excaliard Pharmaceuticals. In 2006 he was recognized by TIME magazine as an Innovation Leader in the area of microbicidal coatings, and in 2008 received the College of Medicine Basic Research Award.
BMB Home Research Areas BMB Faculty